NEXGEL, Inc. (NASDAQ:NXGL – Get Free Report) CEO Adam R. Levy sold 4,000 shares of NEXGEL stock in a transaction dated Monday, February 3rd. The stock was sold at an average price of $3.64, for a total value of $14,560.00. Following the sale, the chief executive officer now directly owns 378,284 shares of the company’s stock, valued at approximately $1,376,953.76. This trade represents a 1.05 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.
NEXGEL Price Performance
NXGL stock traded down $0.00 during mid-day trading on Wednesday, hitting $3.54. 16,552 shares of the stock were exchanged, compared to its average volume of 122,685. The company has a debt-to-equity ratio of 0.19, a current ratio of 1.51 and a quick ratio of 0.93. The business has a fifty day moving average price of $3.85 and a 200 day moving average price of $3.19. NEXGEL, Inc. has a 12 month low of $1.84 and a 12 month high of $5.10. The stock has a market capitalization of $24.03 million, a price-to-earnings ratio of -6.10 and a beta of 0.57.
Institutional Inflows and Outflows
An institutional investor recently bought a new position in NEXGEL stock. IFP Advisors Inc purchased a new stake in shares of NEXGEL, Inc. (NASDAQ:NXGL – Free Report) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund purchased 11,000 shares of the company’s stock, valued at approximately $49,000. IFP Advisors Inc owned 0.16% of NEXGEL at the end of the most recent reporting period. Institutional investors and hedge funds own 2.21% of the company’s stock.
NEXGEL Company Profile
NEXGEL, Inc manufactures high water content, electron beam cross-linked, and aqueous polymer hydrogels and gels. Its products are used for wound care, medical diagnostics, transdermal drug delivery, and cosmetics. The company was formerly known as AquaMed Technologies, Inc and changed its name to NEXGEL, Inc in November 2019.
Featured Stories
- Five stocks we like better than NEXGEL
- How to Calculate Return on Investment (ROI)
- 3 Must-Have ETFs Set to Dominate This Quarter
- How Investors Can Identify and Successfully Trade Gap-Down Stocks
- Seeking Stability? These 3 Stocks Offer Strong Potential
- What Are Trending Stocks? Trending Stocks Explained
- Trade War Bargain Stocks: Top 3 Picks Too Good to Pass Up
Receive News & Ratings for NEXGEL Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NEXGEL and related companies with MarketBeat.com's FREE daily email newsletter.
